| Literature DB >> 35455331 |
Anna Cantarutti1,2, Elisa Barbieri3, Fabio Didonè2, Antonio Scamarcia4, Carlo Giaquinto3, Giovanni Corrao1,2.
Abstract
BACKGROUND: Seasonal influenza can cause serious morbidity, mortality, and financial burden in pediatric and adult populations. The influenza vaccine (IV) is considered the most effective way to prevent influenza and influenza-like-illness (ILI) complications.Entities:
Keywords: influenza vaccination; primary care; real-world evidence; vaccine effectiveness
Year: 2022 PMID: 35455331 PMCID: PMC9031219 DOI: 10.3390/vaccines10040582
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Definition of exposure to assess the additive effect of the influenza vaccine repeated in at least two consecutive seasons.
Figure 2Definition of exposure to assess the prolonged effect of the influenza vaccine performed in a previous season on the following season.
Figure 3The trend of influenza vaccination among influenza seasons of interest from 1 October 2009 to 30 April 2019. Pedianet, 2009–2019.
Figure 4Adjusted hazard ratio and 95% CI for the association between influenza vaccination exposure during each season of interest (from October to April of each year) with influenza and influenza-related complications. Pedianet, 2009–2019.
Adjusted hazard ratio and 95% CI for evaluation of additive and prolonged effect of influenza vaccination among concomitant influenza seasons. Pedianet, 2009–2019.
| Children | Influenza and ILI | |||||
|---|---|---|---|---|---|---|
| Exposed | Unexposed | Exposed | Unexposed | HR | (95% CI) | |
| Additive effect | 10,202 | 3128 | 388 | 129 | 0.91 | (0.74–1.11) |
| Prolonged effect | 5138 | 133,838 | 524 | 11,953 | 0.97 | (0.89–1.06) |